Try Alerts Free   |   Login
Health Care › In Vitro And In Vivo Diagnostic Substances

Akers Biosciences (AKER) Financials and Smart Investor 13F Alerts

See how revenue, income, cash flow, and balance sheet financials have changed over 28 quarters since 2014. Compare with AKER stock chart to see long term trends.

AKER stock compared to

AKER Income Statement

Revenue, Net:null
Cost of Goods & Services Sold:null
Selling, General & Admin Expense:-4990
Research & Development Expense:1823191
Operating Income:-2111988
Net Income:-3286745
Earnings Per Share, Basic:0.72
Shares Outstanding, Basic Avg:7052686

AKER Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:695
Change in Accounts Receiveable:24241
Net Cash from Operations:-3082074
Net Cash from Financing Activities:16362786
Net Cash from Investing Activities:-10967502
Net Change in Cash & Equivalents:2313210

AKER Balance Sheet

Cash and Cash Equivalents:18617955
Short-Term Investments:16718452
Accounts Receivable, Net:null
Inventories:197723
Total Current Assets:36842761
Property, Plant & Equipment, Net:null
Total Assets:36842761
Accounts Payable:2203902
Total Short-Term Liabilities:2263295
Total Liabilities:2263295

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Sabby Management, LLC
299,913 sh
299,913 sh
NEW
$675
$675
Vanguard Group Inc
36,205 sh
36,205 sh
NEW
$82
$82
Blackrock Inc.
6,851 sh
-1 sh
0%
$15
-$9
Bank Of America Corp /De/
31 sh
-492 sh
-94%
$0
-$2
Morgan Stanley
10 sh
 
$0
Virtu Financial LLC
0 sh
-19,971 sh
-100%
$0
-$69
Proequities, Inc.
0 sh
 
$0

Data imported from Akers Biosciences Inc SEC filings. Check original filings before making any investment decision.